Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Pharmacology and therapeutic potential of interferons.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
US court permits generic version of Teva MS drug a year sooner
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Oxidative modification of serum proteins in multiple sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Genzyme’s Lemtrada Approved by the FDA
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
More to come: humoral immune responses in MS.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.

Pages